Clinical trial • Phase III • Immunology
Clinical trial in Psoriasis
Phase III trial for Psoriasis. 18 participants.
Overview
- Trial Therapeutic Area
- Immunology
- Trial Disease
- Psoriasis
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 03-11-2025
- First CTIS Authorization Date
- 22-12-2025
Trial design
Phase III trial across 1 site in Netherlands.
- Target Sample Size
- 18
Eligibility
Recruits 18 No vulnerable populations selected (isVulnerablePopulationSelected: false). Participants are healthy volunteers; no vulnerable-consent/assent procedures are described in the record..
- Vulnerable Population
- No vulnerable populations selected (isVulnerablePopulationSelected: false). Participants are healthy volunteers; no vulnerable-consent/assent procedures are described in the record.
Recruitment
- Planned Sample Size
- 18
- Recruitment Window Months
- 4
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 18
Netherlands
- Earliest CTIS Part Ii Submission Date
- 05-12-2025
- Latest Decision Or Authorization Date
- 22-12-2025
- Processing Time Days
- 17
- Number Of Sites
- 1
- Number Of Participants
- 18
Sites
- Site Name
- Pharmaceutical Research Associates Group B.V.
- Department Name
- Program Management
- Contact Person Name
- Salah Hadi
- Contact Person Email
- salah.hadi@iconplc.com
Sponsor
Primary sponsor
- Full Name
- Janssen Cilag International
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Belgium
Contract research organisations
- Name
- Pharmaceutical Research Associates Group B.V.
- Responsibilities
- Program Management; site contact (contact: salah.hadi@iconplc.com)
Related trials
Other published trials that may interest you.